ALERT

Serious adverse effects resulting from the treatment with thalidomide prompted modern drug legislation more than 40 years ago. Post-marketing spontaneous reporting systems for suspected adverse drug reactions (ADRs) have been a cornerstone to detect safety signals in pharmacovigilance. It has become evident that adverse effects of drugs may be detected too late, when millions of persons have already been exposed.

In this project, an alternative approach for the detection of ADR signals will be developed. Rather than relying on the physician's capability and willingness to recognize and report suspected ADRs, the system will systematically calculate the occurrence of disease (potentially ADRs) during specific drug use based on data available in electronic patient records. In this project, electronic health records (EHRs) of over 30 million patients from several European countries will be available. In an environment where rapid signal detection is feasible, rapid signal assessment is equally important. To rapidly assess signals, a number of resources will be used to substantiate the signals: causal reasoning based on information in the EHRs, semantic mining of the biomedical literature, and computational analysis of biological and chemical information (drugs, targets, anti-targets, SNPs, pathways, etc.).

The overall objective of this project is the design, development and validation of a computerized system that exploits data from electronic healthcare records and biomedical databases for the early detection of adverse drug reactions. The ALERT system will generate signals using data and text mining, epidemiological and other computational techniques, and subsequently substantiate these signals in the light of current knowledge of biological mechanisms and in silico prediction capabilities. The system should be able to detect signals better and faster than spontaneous reporting systems and should allow for identification of subpopulations at higher risk for ADRs.

For further information, please visit:

Project co-ordinator:
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Partners:

  • SOCIETA SERVIZI TELEMATICI SRL
  • UNIVERSIDADE DE AVEIRO
  • THE UNIVERSITY OF NOTTINGHAM
  • PHARMO COOPERATIE UA
  • AARHUS UNIVERSITETSHOSPITAL, AARHUS SYGEHUS
  • UNIVERSIDADE DE SANTIAGO DE COMPOSTELA
  • UNIVERSITAT POMPEU FABRA
  • IRCCS CENTRO NEUROLESI BONINO PULEJO
  • FUNDACIO IMIM
  • LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
  • ASTRAZENECA AB
  • UNIVERSITE VICTOR SEGALEN BORDEAUX II
  • AGENZIA REGIONALE DI SANITA
  • UNIVERSITA DEGLI STUDI DI MILANO - BICOCCA

Timetable: from 02/2008 – to 07/2011

Total cost: € 5.880.600

EC funding: € 4.500.000

Programme Acronym: FP7-ICT

Subprogramme Area: Advanced ICT for risk assessment and patient safety

Contract type: Collaborative project (generic)

Related news article:

Most Popular Now

AI Distinguishes Glioblastoma from Look-…

A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments. The...

AI Body Composition Measurements can Pre…

Adiposity - or the accumulation of excess fat in the body - is a known driver of cardiometabolic diseases such as heart disease, stroke, type 2 diabetes, and kidney disease...

'Future-Guided' AI Improves Se…

In the world around us, many things exist in the context of time: a bird’s path through the sky is understood as different positions over a period of time, and...

AI can Strengthen Pandemic Preparedness

How to identify the next dangerous virus before it spreads among people is the central question in a new Comment in The Lancet Infectious Diseases. In it, researchers discuss how...